Organogenesis Holdings (ORGO) Free Cash Flow (2016 - 2026)

Organogenesis Holdings' Free Cash Flow history runs 11 years deep, the most recent figure standing at $18.0 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 176.32% year-over-year to $18.0 million in Q1 2026; TTM through Mar 2026 was $17.1 million, a 302.47% increase from a year earlier, with the FY2025 full-year figure at -$24.5 million, down 685.73% from the prior year.
• Free Cash Flow declined to $18.0 million in Q1 2026 per ORGO's latest filing, from $34.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $34.8 million in Q4 2025 and bottomed at -$36.5 million in Q2 2025.
• The 5-year median for Free Cash Flow is -$458000.0 (2022), against an average of -$281705.9.
• Across the five-year window, Free Cash Flow jumped 1227.58% in 2023 and tumbled 2667.58% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$2.9 million in 2022, then surged by 355.25% to $7.3 million in 2023, then climbed by 3.92% to $7.6 million in 2024, then surged by 358.92% to $34.8 million in 2025, then slumped by 48.28% to $18.0 million in 2026.
• Per Business Quant, the three latest ORGO Free Cash Flow figures stand at $18.0 million (Q1 2026), $34.8 million (Q4 2025), and $844000.0 (Q3 2025).